Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A sound preclinical study combining in vitro and in vivo work in a mouse TNBC model, demonstrating mechanistic plausibility and efficacy enhancement, but lacking human data, clinical endpoints, or direct comparison to standard anti-angiogenic therapy.
Mechanistic study using transcriptomics and experimental models to propose a resistance pathway; lacks clinical trial evidence or outcome validation of the proposed therapeutic strategy.
A narrative review synthesizing mechanistic concepts and therapeutic strategies without presenting primary empirical data, clinical trials, or meta-analyses; raises questions about NO-based cancer interventions rather than testing them.
This is a narrative mechanistic review synthesizing literature on tumor vasculogenesis pathways; it raises questions about therapeutic targeting rather than testing a specific hypothesis through empirical study.
A sound but limited preclinical study in knockout mice showing RGS5 deletion prevents diet-induced cerebrovascular pathology and spatial memory deficits, needing confirmation in larger or human studies.
A narrative review synthesizing mechanistic biology and case evidence that identifies a biologically plausible but clinically unproven hypothesis about VEGFR inhibition in hemoptysis, explicitly noting absence of controlled trials and the paradoxical risk of fatal hemorrhage.
This is early-stage drug discovery work using computational and in vitro methods to identify a lead compound; it lacks any in vivo efficacy data, clinical outcomes, or human studies needed to support therapeutic claims.